

Amit Bar-or

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1042805/publications.pdf>

Version: 2024-02-01

214
papers

25,087
citations

8732

75
h-index

7496

151
g-index

227
all docs

227
docs citations

227
times ranked

20283
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea in multiple sclerosis: A randomized, double-blind, placebo-controlled trial (SAMS-PAP study). <i>Multiple Sclerosis Journal</i> , 2022, 28, 82-92.	1.4	3
2	Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. <i>Multiple Sclerosis Journal</i> , 2022, 28, 801-816.	1.4	26
3	Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 910-924.	1.4	27
4	Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome. <i>Neurology</i> , 2022, 98, .	1.5	15
5	Accumulation of meningeal lymphocytes correlates with white matter lesion activity in progressive multiple sclerosis. <i>JCI Insight</i> , 2022, 7, .	2.3	16
6	The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1299-1310.	1.4	4
7	Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide. <i>Frontiers in Neurology</i> , 2022, 13, 828616.	1.1	4
8	Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1819-1824.	1.4	2
9	BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy. <i>Acta Neuropathologica</i> , 2022, 143, 505-521.	3.9	29
10	Pathways to cures for multiple sclerosis: A research roadmap. <i>Multiple Sclerosis Journal</i> , 2022, 28, 331-345.	1.4	9
11	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naïve patients with multiple sclerosis: Results from ASCLEPIOS I and II. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1562-1575.	1.4	25
12	Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1526-1540.	1.4	16
13	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1591-1605.	1.4	19
14	Progressive retinal changes in pediatric multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103761.	0.9	2
15	Abnormal B-Cell and Tfh-Cell Profiles in Patients With Parkinson Disease. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	3.1	21
16	Guilty by association: Epstein-Barr virus in multiple sclerosis. <i>Nature Medicine</i> , 2022, 28, 904-906.	15.2	15
17	The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103829.	0.9	8
18	Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1697-1709.	1.4	12

#	ARTICLE	IF	CITATIONS
19	033â€¦ Ocrelizumab: serum Ig levels and serious infections. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A23.3-A24.	0.9	0
20	043â€¦ Efficacy of siponimod in secondary progressive multiple sclerosis with active disease: EXPAND study subgroup analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A27.1-A27.	0.9	0
21	Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of Neurology, 2022, 269, 5093-5104.	1.8	7
22	045â€¦ Effect of siponimod on cortical grey matter and thalamic volume in secondary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A27.3-A27.	0.9	0
23	116â€¦ Serum immunoglobulin levels and infection risk in Phase 3 ofatumumab trials in relapsing multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A137.2-A137.	0.9	0
24	113â€¦ Benefit-risk of ofatumumab in treatment-naïve early relapsing multiple sclerosis patients. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A136.2-A136.	0.9	1
25	010â€¦ Safety and efficacy of long-term dimethyl fumarate treatment. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A16.4-A17.	0.9	0
26	Emerging therapies to target CNS pathophysiology in multiple sclerosis. Nature Reviews Neurology, 2022, 18, 466-475.	4.9	25
27	Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. Multiple Sclerosis Journal, 2022, 28, 1927-1936.	1.4	10
28	Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations. Current Opinion in Neurology, 2022, 35, 319-327.	1.8	12
29	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5â€‰%years of follow-up in the DAYBREAK open-label extension trial. Multiple Sclerosis Journal, 2022, 28, 1944-1962.	1.4	16
30	Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1564-1576.	1.4	16
31	Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. Multiple Sclerosis Journal, 2021, 27, 1814-1822.	1.4	19
32	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. Multiple Sclerosis Journal, 2021, 27, 922-932.	1.4	5
33	Role of B Cells in Multiple Sclerosis and Related Disorders. Annals of Neurology, 2021, 89, 13-23.	2.8	123
34	Silent New Brain MRI Lesions in Children with MOGâ€‰Antibody Associated Disease. Annals of Neurology, 2021, 89, 408-413.	2.8	33
35	Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2021, 78, 48.	4.5	11
36	Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1948-1959.	1.4	9

#	ARTICLE	IF	CITATIONS
37	Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study. <i>Neurology</i> , 2021, 96, 870-870.	1.5	2
38	Examining cognitive speed and accuracy dysfunction in youth and young adults with pediatric-onset multiple sclerosis using a computerized neurocognitive battery.. <i>Neuropsychology</i> , 2021, 35, 388-398.	1.0	5
39	Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances. <i>Lancet Neurology</i> , The, 2021, 20, 470-483.	4.9	96
40	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 51, 102844.	0.9	19
41	Meningeal B Cell Clusters Correlate with Submeningeal Pathology in a Natural Model of Multiple Sclerosis. <i>Journal of Immunology</i> , 2021, 207, 44-54.	0.4	8
42	B cells in multiple sclerosis – from targeted depletion to immune reconstitution therapies. <i>Nature Reviews Neurology</i> , 2021, 17, 399-414.	4.9	110
43	Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1033-1043.	0.9	26
44	CCR6 Expression on B Cells Is Not Required for Clinical or Pathological Presentation of MOG Protein-Induced Experimental Autoimmune Encephalomyelitis despite an Altered Germinal Center Response. <i>Journal of Immunology</i> , 2021, 207, 1513-1521.	0.4	1
45	Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis. <i>CNS Drugs</i> , 2021, 35, 985-997.	2.7	26
46	Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. <i>Nature Medicine</i> , 2021, 27, 1990-2001.	15.2	396
47	Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 729-738.	4.9	89
48	Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 918-928.	1.7	21
49	Siponimod and Cognition in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e376-e386.	1.5	64
50	Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes. <i>JAMA Network Open</i> , 2021, 4, e2128871.	2.8	27
51	Multiple sclerosis meets systems immunology – Authors' reply. <i>Lancet Neurology</i> , The, 2021, 20, 888.	4.9	0
52	Disrupted cognitive development following pediatric acquired demyelinating syndromes: a longitudinal study. <i>Child Neuropsychology</i> , 2021, , 1-22.	0.8	0
53	The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2252-2269.	1.7	34
54	Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. <i>JAMA Neurology</i> , 2020, 77, 82.	4.5	213

#	ARTICLE	IF	CITATIONS
55	Factors associated with health care utilization in pediatric multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101511.	0.9	7
56	Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. <i>Trends in Molecular Medicine</i> , 2020, 26, 296-310.	3.5	178
57	Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2020, 16, 56-62.	4.9	71
58	Deep learning segmentation of orbital fat to calibrate conventional MRI for longitudinal studies. <i>NeuroImage</i> , 2020, 208, 116442.	2.1	17
59	Five years of ocrelizumab in relapsing multiple sclerosis. <i>Neurology</i> , 2020, 95, e1854-e1867.	1.5	81
60	Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS. <i>Acta Neuropathologica Communications</i> , 2020, 8, 207.	2.4	11
61	Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis. <i>Neurology</i> , 2020, 95, e1999-e2008.	1.5	269
62	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2020, 383, 546-557.	13.9	358
63	Multiplexed detection and isolation of viable low-frequency cytokine-secreting human B cells using cytokine secretion assay and flow cytometry (CSA-Flow). <i>Scientific Reports</i> , 2020, 10, 14823.	1.6	5
64	Unraveling B lymphocytes in CNS inflammatory diseases. <i>Neurology</i> , 2020, 95, 733-744.	1.5	10
65	The Identity of Human Tissue-Emigrant CD8+ T Cells. <i>Cell</i> , 2020, 183, 1946-1961.e15.	13.5	58
66	COVID-19 and MS disease-modifying therapies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	91
67	Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642091500.	1.5	47
68	Neurological immunotherapy in the era of COVID-19 – looking for consensus in the literature. <i>Nature Reviews Neurology</i> , 2020, 16, 493-505.	4.9	57
69	Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis. <i>Scientific Reports</i> , 2020, 10, 356.	1.6	24
70	Advances in oral immunomodulating therapies in relapsing multiple sclerosis. <i>Lancet Neurology</i> , The, 2020, 19, 336-347.	4.9	90
71	Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGM study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 483-492.	0.9	26
72	Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 767-775.	1.7	20

#	ARTICLE	IF	CITATIONS
73	Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. <i>Neurology: Clinical Practice</i> , 2020, 10, 510-519.	0.8	17
74	Editorial: Update on Translational Neuroimmunology - Research of ISNI 2018. <i>Frontiers in Immunology</i> , 2020, 11, 1212.	2.2	1
75	Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI. <i>Multiple Sclerosis Journal</i> , 2019, 25, 980-986.	1.4	11
76	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1255-1262.	1.4	37
77	A framework for measurement and harmonization of pediatric multiple sclerosis etiologic research studies: The Pediatric MS Tool-Kit. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1170-1177.	1.4	3
78	Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	45
79	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology</i> , The, 2019, 18, 1009-1020.	4.9	191
80	Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. <i>Neurology</i> , 2019, 93, e1778-e1786.	1.5	37
81	Early neuroaxonal injury is seen in the acute phase of pediatric optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101387.	0.9	4
82	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology</i> , The, 2019, 18, 1021-1033.	4.9	184
83	High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study. <i>PLoS ONE</i> , 2019, 14, e0218215.	1.1	15
84	Exosome-enriched fractions from MS B cells induce oligodendrocyte death. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019, 6, e550.	3.1	26
85	Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	92
86	Effect of dimethyl fumarate on lymphocytes in RRMS. <i>Neurology</i> , 2019, 92, e1724-e1738.	1.5	66
87	A surfaceâ€”in gradient of thalamic damage evolves in pediatric multiple sclerosis. <i>Annals of Neurology</i> , 2019, 85, 340-351.	2.8	42
88	Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis. <i>Brain</i> , 2019, 142, 617-632.	3.7	72
89	Pediatric-onset multiple sclerosis is associated with reduced parental healthâ€”related quality of life and family functioning. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1661-1672.	1.4	21
90	Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10. <i>Cell</i> , 2019, 176, 610-624.e18.	13.5	241

#	ARTICLE	IF	CITATIONS
91	The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731881924.	0.5	3
92	The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk. <i>Multiple Sclerosis Journal</i> , 2019, 25, 515-522.	1.4	32
93	The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a029108.	2.9	17
94	T follicular helper cells in human efferent lymph retain lymphoid characteristics. <i>Journal of Clinical Investigation</i> , 2019, 129, 3185-3200.	3.9	116
95	MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 191-204.	2.7	86
96	Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis. <i>Neurology</i> , 2018, 90, e1805-e1814.	1.5	165
97	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731876064.	0.5	32
98	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet</i> , The, 2018, 391, 1263-1273.	6.3	684
99	Differential transcriptional response profiles in human myeloid cell populations. <i>Clinical Immunology</i> , 2018, 189, 63-74.	1.4	15
100	Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS. <i>Multiple Sclerosis Journal</i> , 2018, 24, 632-641.	1.4	57
101	Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 501-511.	1.4	86
102	Multiple sclerosis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 43.	18.1	767
103	Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e499.	3.1	4
104	Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2018, 379, 1017-1027.	13.9	237
105	Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2018, 9, 834.	2.2	51
106	Isotype-Switched Autoantibodies Are Necessary To Facilitate Central Nervous System Autoimmune Disease in <i>Aicda</i> ^{-/-} and <i>Ung</i> ^{-/-} Mice. <i>Journal of Immunology</i> , 2018, 201, 1119-1130.	0.4	15
107	Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis. <i>Journal of Neuroinflammation</i> , 2018, 15, 114.	3.1	40
108	Neuroimmune disorders of the central nervous system in children in the molecular era. <i>Nature Reviews Neurology</i> , 2018, 14, 433-445.	4.9	41

#	ARTICLE	IF	CITATIONS
109	Reassessing B cell contributions in multiple sclerosis. <i>Nature Immunology</i> , 2018, 19, 696-707.	7.0	275
110	Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses. <i>Journal of Immunology</i> , 2017, 198, 3245-3254.	0.4	31
111	B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro. <i>Journal of Neuroimmunology</i> , 2017, 309, 88-99.	1.1	85
112	White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders. <i>Brain</i> , 2017, 140, 1300-1315.	3.7	52
113	Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e340.	3.1	73
114	Monophasic demyelination reduces brain growth in children. <i>Neurology</i> , 2017, 88, 1744-1750.	1.5	43
115	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 221-234.	13.9	1,322
116	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 209-220.	13.9	1,324
117	Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis. <i>Journal of Immunology</i> , 2017, 198, 691-698.	0.4	112
118	Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1225-1232.	1.4	32
119	Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment. <i>Multiple Sclerosis Journal</i> , 2017, 23, 567-576.	1.4	15
120	MerTK-mediated regulation of myelin phagocytosis by macrophages generated from patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e402.	3.1	49
121	Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. <i>JCI Insight</i> , 2016, 1, .	2.3	356
122	Central nervous system inflammation across the age span. <i>Current Opinion in Neurology</i> , 2016, 29, 381-387.	1.8	9
123	Restoring immune tolerance in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e277.	3.1	39
124	Restoring immune tolerance in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e276.	3.1	35
125	Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases. <i>Neurology</i> , 2016, 87, S12-9.	1.5	49
126	Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism. <i>Stem Cells Translational Medicine</i> , 2016, 5, 1506-1514.	1.6	73

#	ARTICLE	IF	CITATIONS
127	Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases. <i>Immunological Reviews</i> , 2016, 269, 130-144.	2.8	50
128	Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. <i>Lancet, The</i> , 2016, 388, 576-585.	6.3	296
129	MerTK Is a Functional Regulator of Myelin Phagocytosis by Human Myeloid Cells. <i>Journal of Immunology</i> , 2016, 196, 3375-3384.	0.4	128
130	Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology, The</i> , 2016, 15, 373-381.	4.9	150
131	Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 103-118.	1.7	48
132	Sequencing the immunopathologic heterogeneity in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 873-874.	1.7	1
133	B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation. <i>Frontiers in Immunology</i> , 2015, 6, 636.	2.2	120
134	TLR2 Stimulation Regulates the Balance between Regulatory T Cell and Th17 Function: A Novel Mechanism of Reduced Regulatory T Cell Function in Multiple Sclerosis. <i>Journal of Immunology</i> , 2015, 194, 5761-5774.	0.4	65
135	P2Y12 expression and function in alternatively activated human microglia. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e80.	3.1	139
136	Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. <i>Neurology and Therapy</i> , 2015, 4, 93-104.	1.4	80
137	Integration of Th17- and Lymphotoxin-Derived Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate Neuroinflammation. <i>Immunity</i> , 2015, 43, 1160-1173.	6.6	176
138	Recovery From Central Nervous System Acute Demyelination in Children. <i>Pediatrics</i> , 2015, 136, e115-e123.	1.0	40
139	Roles of microglia in brain development, tissue maintenance and repair. <i>Brain</i> , 2015, 138, 1138-1159.	3.7	316
140	Puberty in females enhances the risk of an outcome of multiple sclerosis in children and the development of central nervous system autoimmunity in mice. <i>Multiple Sclerosis Journal</i> , 2015, 21, 735-748.	1.4	47
141	Coexpression of TIGIT and FCRL3 Identifies Helios+ Human Memory Regulatory T Cells. <i>Journal of Immunology</i> , 2015, 194, 3687-3696.	0.4	115
142	Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. <i>Science Translational Medicine</i> , 2015, 7, 310ra166.	5.8	334
143	B lymphocytes in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e104.	3.1	132
144	Neuroinflammation: Ways in Which the Immune System Affects the Brain. <i>Neurotherapeutics</i> , 2015, 12, 896-909.	2.1	170

#	ARTICLE	IF	CITATIONS
145	Update on biomarkers in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e134.	3.1	104
146	Direct and Indirect Effects of Immune and Central Nervous Systemâ€œResident Cells on Human Oligodendrocyte Progenitor Cell Differentiation. <i>Journal of Immunology</i> , 2015, 194, 761-772.	0.4	75
147	Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2015, 6, 626.	2.2	69
148	Meningeal Tertiary Lymphoid Tissues and Multiple Sclerosis: A Gathering Place for Diverse Types of Immune Cells during CNS Autoimmunity. <i>Frontiers in Immunology</i> , 2015, 6, 657.	2.2	73
149	Effects of Blood Transportation on Human Peripheral Mononuclear Cell Yield, Phenotype and Function: Implications for Immune Cell Biobanking. <i>PLoS ONE</i> , 2014, 9, e115920.	1.1	43
150	Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. <i>Neurology</i> , 2014, 83, 2219-2226.	1.5	58
151	Teriflunomide and Its Mechanism of Action in Multiple Sclerosis. <i>Drugs</i> , 2014, 74, 659-674.	4.9	274
152	IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. <i>Nature</i> , 2014, 507, 366-370.	13.7	882
153	Rasmussen encephalitis and comorbid autoimmune diseases. <i>Neurology</i> , 2014, 83, 1049-1055.	1.5	22
154	Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 268, 95-98.	1.1	50
155	Teriflunomide (Aubagio®) for the treatment of multiple sclerosis. <i>Experimental Neurology</i> , 2014, 262, 57-65.	2.0	36
156	A Novel MicroRNA-132-Sirtuin-1 Axis Underlies Aberrant B-cell Cytokine Regulation in Patients with Relapsing-Remitting Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e105421.	1.1	81
157	miR-155 as a multiple sclerosisâ€œrelevant regulator of myeloid cell polarization. <i>Annals of Neurology</i> , 2013, 74, 709-720.	2.8	189
158	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsingâ€œremitting multiple sclerosis: subgroup analyses of the DEFINE study. <i>Journal of Neurology</i> , 2013, 260, 2297-2305.	1.8	62
159	B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6â€œproducing B cells. <i>Journal of Experimental Medicine</i> , 2012, 209, 1001-1010.	4.2	530
160	<sc>B</sc> cells set trends: Lessons from multiple sclerosis. <i>Clinical and Experimental Neuroimmunology</i> , 2012, 3, 89-108.	0.5	1
161	Laquinimod in multiple sclerosis. <i>Clinical Immunology</i> , 2012, 142, 38-43.	1.4	16
162	Treatment of multiple sclerosis with Anti-CD20 antibodies. <i>Clinical Immunology</i> , 2012, 142, 31-37.	1.4	118

#	ARTICLE	IF	CITATIONS
163	From bench to MS bedside: Challenges translating biomarker discovery to clinical practice. <i>Journal of Neuroimmunology</i> , 2012, 248, 66-72.	1.1	9
164	Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. <i>Journal of Neuroimmunology</i> , 2012, 246, 85-95.	1.1	145
165	Autoantibodies against aquaporin-4 and myelin oligodendrocyte glycoprotein in paediatric CNS demyelination: Recent developments and future directions. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 116-122.	0.9	3
166	Targeting Progressive Neuroaxonal Injury. <i>CNS Drugs</i> , 2011, 25, 783-799.	2.7	25
167	Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 997-998.	0.8	77
168	Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2011, 378, 1779-1787.	6.3	636
169	The immunology of multiple sclerosis. , 2011, , 20-34.		6
170	Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. <i>Lancet Neurology, The</i> , 2011, 10, 436-445.	4.9	267
171	Therapies for multiple sclerosis: considerations in the pediatric patient. <i>Nature Reviews Neurology</i> , 2011, 7, 109-122.	4.9	43
172	A proteome map of axoglial specializations isolated and purified from human central nervous system. <i>Glia</i> , 2010, 58, 1949-1960.	2.5	46
173	Abnormal B cell cytokine responses a trigger of T cell mediated disease in MS?. <i>Annals of Neurology</i> , 2010, 67, 452-461.	2.8	428
174	EBV and brain matter(s)?. <i>Neurology</i> , 2010, 74, 1092-1095.	1.5	18
175	Evidence of in vivo Immune Modulation with Vitamin D3 and Calcium Supplementation in Multiple Sclerosis. <i>FASEB Journal</i> , 2010, 24, 537.23.	0.2	0
176	Age-Dependent B Cell Autoimmunity to a Myelin Surface Antigen in Pediatric Multiple Sclerosis. <i>Journal of Immunology</i> , 2009, 183, 4067-4076.	0.4	182
177	Antigen-specific therapies in multiple sclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 551-560.	1.0	8
178	Myelin regulates immune cell adhesion and motility. <i>Experimental Neurology</i> , 2009, 217, 371-377.	2.0	30
179	Emerging multiple sclerosis disease-modifying therapies. <i>Current Opinion in Neurology</i> , 2009, 22, 226-232.	1.8	21
180	Abnormal T cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. <i>Annals of Neurology</i> , 2008, 63, 98-111.	2.8	77

#	ARTICLE	IF	CITATIONS
181	Rituximab in relapsing–remitting multiple sclerosis: A 72–week, open–label, phase I trial. <i>Annals of Neurology</i> , 2008, 63, 395-400.	2.8	484
182	B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators. <i>Nature Reviews Immunology</i> , 2008, 8, 486-487.	10.6	45
183	Elevated serum inflammatory markers in post-poliomyelitis syndrome. <i>Journal of the Neurological Sciences</i> , 2008, 271, 80-86.	0.3	34
184	B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2008, 358, 676-688.	13.9	2,107
185	Functional Consequences of Neuromyelitis Optica-IgG Astrocyte Interactions on Blood-Brain Barrier Permeability and Granulocyte Recruitment. <i>Journal of Immunology</i> , 2008, 181, 5730-5737.	0.4	233
186	The Immunology of Multiple Sclerosis. <i>Seminars in Neurology</i> , 2008, 28, 029-045.	0.5	117
187	Beta interferons in clinically isolated syndromes: a meta-analysis. <i>Arquivos De Neuro-Psiquiatria</i> , 2008, 66, 8-10.	0.3	5
188	Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis. <i>Journal of Immunology</i> , 2007, 178, 6092-6099.	0.4	567
189	Induction of Antigen-Specific Tolerance in Multiple Sclerosis After Immunization With DNA Encoding Myelin Basic Protein in a Randomized, Placebo-Controlled Phase 1/2 Trial. <i>Archives of Neurology</i> , 2007, 64, 1407.	4.9	159
190	Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia. <i>Glia</i> , 2007, 55, 516-526.	2.5	87
191	Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. <i>Nature Medicine</i> , 2007, 13, 211-217.	15.2	342
192	Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. <i>Lancet Neurology</i> , The, 2007, 6, 773-781.	4.9	292
193	Roles of immunoglobulins and B cells in multiple sclerosis: From pathogenesis to treatment. <i>Journal of Neuroimmunology</i> , 2006, 180, 3-8.	1.1	80
194	Natalizumab effects on immune cell responses in multiple sclerosis. <i>Annals of Neurology</i> , 2006, 59, 748-754.	2.8	190
195	Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. <i>Archives of Neurology</i> , 2006, 63, 1383.	4.9	271
196	Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. <i>Journal of Neuroimmunology</i> , 2005, 158, 213-221.	1.1	102
197	Microglia and multiple sclerosis. <i>Journal of Neuroscience Research</i> , 2005, 81, 363-373.	1.3	174
198	Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS. <i>Journal of Neuroscience</i> , 2005, 25, 2537-2546.	1.7	150

#	ARTICLE	IF	CITATIONS
199	Immunology of multiple sclerosis. <i>Neurologic Clinics</i> , 2005, 23, 149-175.	0.8	29
200	Distinct Profiles of Human B Cell Effector Cytokines: A Role in Immune Regulation?. <i>Journal of Immunology</i> , 2004, 172, 3422-3427.	0.4	316
201	Type 2 Monocyte and Microglia Differentiation Mediated by Glatiramer Acetate Therapy in Patients with Multiple Sclerosis. <i>Journal of Immunology</i> , 2004, 172, 7144-7153.	0.4	187
202	Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients. <i>Clinical Immunology</i> , 2004, 111, 38-46.	1.4	18
203	Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. <i>Journal of Neuroimmunology</i> , 2003, 136, 140-148.	1.1	92
204	Differential effects of Th1 and Th2 lymphocyte supernatants on human microglia. <i>Glia</i> , 2003, 42, 36-45.	2.5	35
205	Determinants of Human B Cell Migration Across Brain Endothelial Cells. <i>Journal of Immunology</i> , 2003, 170, 4497-4505.	0.4	175
206	Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. <i>Brain</i> , 2003, 126, 2738-2749.	3.7	300
207	Do Myelin-Directed Antibodies Predict Multiple Sclerosis?. <i>New England Journal of Medicine</i> , 2003, 349, 107-109.	13.9	37
208	The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. <i>Journal of Clinical Immunology</i> , 2001, 21, 81-92.	2.0	155
209	Immunological Memory: Contribution of Memory B Cells Expressing Costimulatory Molecules in the Resting State. <i>Journal of Immunology</i> , 2001, 167, 5669-5677.	0.4	126
210	Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population. <i>Nature Medicine</i> , 2000, 6, 211-214.	15.2	69
211	Biology of Adult Human Microglia in Culture: Comparisons with Peripheral Blood Monocytes and Astrocytes. <i>Journal of Neuropathology and Experimental Neurology</i> , 1992, 51, 538-549.	0.9	153
212	Urinary 6-sulphatoxymelatonin, an index of pineal function in the rat. <i>Journal of Pineal Research</i> , 1991, 10, 141-147.	3.4	54
213	Pineal involvement in the diurnal rhythm of nociception in the rat. <i>Life Sciences</i> , 1989, 44, 1067-1075.	2.0	32
214	B-cell-based therapies for multiple sclerosis. , 0 , 483-497.		0